Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer

Phase

N/A

Condition

Pancreatic Cancer

Pancreatic Disorders

Adenocarcinoma

Treatment

LINFU™ Technique

Clinical Study ID

NCT04793633

Adenocyte 110

Ages 18-90
All Genders

Study Summary

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions. The test involves ultrasound and an analysis of pancreatic juice. A neural network-based computer-assisted system may be utilized to enhance the analysis. Patients enrolled are being screened for pancreatic cancer because they have known risk factors (i.e. smoking, diabetes, chronic pancreatitis, family history of pancreatic cancer, or certain genetic syndromes).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Both males and females will be enrolled and must be at least 18 years of age and under age of 90
Patients, who in the opinion of the Investigator, are at elevated risk of developing a pancreatic malignancy because they have known risk factors for PDAC or signs or symptoms of PDAC
High risk asymptomatic patients being screened for PDAC
Patients with clinical signs or symptoms of PDAC including abnormal imaging and who are scheduled for EUS- FNA, MRI/MRCP, ERCP, or CT will be enrolled
Institutional Review Board (IRB)-approved consent must be signed by patients to participate in this study.

Exclusion Criteria

Patient under the age of 18 and over the age 90
Contraindications to LINFU/EUS/ERCP as determined by study investigators:
Patient with uncorrectable coagulopathy
Patient that cannot undergo anesthesia due to cardiopulmonary contraindication as deemed by the anesthesiologist
Unstable medically (cardiopulmonary, neurologic, or cardiovascular status)
Patients undergoing EUS or ERCP for a suspected bile duct cancer arising from the intrahepatic or extrahepatic biliary epithelium
Pregnant females will be excluded
Patient that is unable to provide informed consent
Patient with known allergy to the microbubble contrast agent or secretin

Study Design

LINFU™ Technique

January 31, 2024

December 30, 2030

Study Description

Adenocyte has developed a proprietary pancreatic cancer detection method, LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) to increase the sensitivity of pancreatic juice cytology. LINFU® consists of analysis of pancreatic fluid collected with the help of low intensity non-focused ultrasound excitation of the pancreas. A contrast agent will be used to create bubbles and possibly increase the number of pancreatic cell we collect for the study. Secretin is also used to increase the number of pancreatic cell excretion to maximize the number of cells collected. A neural network-based computer-assisted system may be used to enhance the analysis of specimens.

In this registry, LINFU® will be studied in patients who are at increased risk for developing pancreatic cancer as well as those with signs or symptoms of disease.

In this registry, a standardized Case Report Form will be completed for every subject enrolled. Information obtained at baseline will include patient history, clinical and demographic information including relevant comorbidities and pancreatic disease history, and screening and pathology test results. The results of all diagnostic tests, surgeries, and biopsies performed after the LINFU® technique for a period of 5 years will be recorded and maintained as clinical registry data. This includes testing and procedures received since enrollment including EUS- FNA, MRI/MRCP, ERCP, CT, CEUS, treatments performed, pathology results, and pancreatic disease history since enrollment.

The registry case report form is the primary data collection instrument for the registry. All data requested on the form must be recorded and these forms will be monitored carefully by the sponsor to ensure they are completely filled out properly.

Connect with a study center

Sarasota Memorial HealthCare System
Sarasota, Florida 34239
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.